Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells
| Autor: | Julie M. Brown, Janna E. Quinn, Eva Corey, Franck Bladou, Lisha G. Brown, Martine Roudier, Robert L. Vessella, Kent R. Buhler |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Pathology medicine.medical_specialty Osteolysis Urology Transplantation Heterologous Osteoclasts Receptors Cytoplasmic and Nuclear Bone Neoplasms Receptors Tumor Necrosis Factor Metastasis Bone remodeling Prostate cancer Osteoprotegerin Bone Density LNCaP Tumor Cells Cultured medicine Animals Humans Glycoproteins Bone growth Membrane Glycoproteins Osteoblasts Endothelin-1 Receptor Activator of Nuclear Factor-kappa B Tibia business.industry RANK Ligand Parathyroid Hormone-Related Protein Prostatic Neoplasms Proteins Bone metastasis medicine.disease Immunohistochemistry Disease Models Animal Kinetics Oncology Bone Remodeling Carrier Proteins business Orchiectomy Neoplasm Transplantation |
| Zdroj: | The Prostate. 52:20-33 |
| ISSN: | 1097-0045 0270-4137 |
| DOI: | 10.1002/pros.10091 |
| Popis: | BACKGROUND To improve the therapy of advanced prostate cancer (CaP), it is critical to develop animal models that mimic CaP bone metastases. Unlike the human disease, CaP xenograft models rarely metastasize spontaneously to bone from the orthotopic site of primary tumor growth. METHODS Single-cell suspensions of LNCaP, PC-3, LuCaP 35, and LuCaP 23.1 CaP cells were injected directly into tibia of SCID mice. Immunohistochemistry and bone histomorphometrical analyses were performed to characterize these osseous-CaP models. RESULTS LuCaP 23.1 yields an osteoblastic response, LNCaP yields mixed lesions, and LuCaP 35 and PC-3 result in osteolytic responses. We have detected osteoprotegerin, RANK ligand, parathyroid hormone-related protein, and endothelin-1, proteins associated with bone growth and remodeling, in the CaP cells grown in the bone. CONCLUSIONS These animal models can be used to study biological interactions, pathways, and potential therapeutic targets, and also to evaluate new agents for treatment and prevention of CaP bone metastasis. Prostate 52: 20–33, 2002. © 2002 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text